A phase I study of LY3022855, a colony stimulating factor-1 receptor (CSF-1 R) inhibitor in patients (pts) with advanced solid tumors.

被引：6

作者：

Dowlati, Afshin

Rugo, Hope S.

Harvey, R. Donald

Kudchadkar, Ragini Reiney

Carvajal, Richard D.

Manji, Gulam Abbas

Hamid, Omid

Klempner, Samuel Jacob

Tang, Shande

Yu, Danni

Kauh, John S.

Schaer, David Arlen

Tate, Sonya Catherine

Wesolowski, Robert

机构：

[1] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA

[2] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94143 USA

[3] Winship Canc Inst, Atlanta, GA USA

[4] Columbia Univ Med Ctr, New York, NY USA

[5] Columbia Univ Med Ctr, New York Presbyterian Hosp, New York, NY USA

[6] Angeles Clin & Res Inst, Los Angeles, CA USA

[7] Univ Calif Irvine, Fullerton, CA USA

[8] Eli Lilly & Co, Bridgewater, NJ USA

[9] Eli Lilly & Co, Indianapolis, IN 46285 USA

[10] Eli Lilly & Co, New York, NY USA

[11] Eli Lilly & Co, Windlesham, Surrey, England

[12] Ohio State Univ, Arthur G James Canc Hosp, Comprehens Canc Ctr, Columbus, OH 43210 USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.2523

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2523

引用

页数：6